Research on H. pylori and gastrointestinal cancer

Medical research has identified new links between Helicobacter pylori (H. pylori) and gastrointestinal health. An international analysis involving 48 million people suggests that H. pylori exposure may be associated with approximately 22% of global colorectal cancer cases, increasing the risk of the disease by 1.59 times. While H. pylori is a known cause of stomach cancer, its connection to bowel cancer has been debated; researchers suggest antibiotic eradication might reduce risk, though benefits may take 10 years to manifest. Additionally, studies indicate that the link between H. pylori and Small Intestinal Bacterial Overgrowth (SIBO) varies by patient due to individual gastric phenotypes.

In cancer treatment developments, the NEOPRISM-CRC clinical trial demonstrated that preoperative immunotherapy using pembrolizumab may offer significant benefits for stage 2 or stage 3 bowel cancer patients, with no recurrences reported after 33 months. Furthermore, researchers at the Santiago de Compostela Health Research Institute have identified molecules in bovine colostrum that can reversibly slow the proliferation of gastrointestinal cancer cells and increase sensitivity to chemotherapy.